2011-24903. Branded Prescription Drug Fee; Correction  

  • Start Preamble

    AGENCY:

    Internal Revenue Service (IRS), Treasury.

    ACTION:

    Correcting amendment.

    SUMMARY:

    This document contains corrections to temporary regulations (TD 9544) that were published in the Federal Register on Thursday, August 18, 2011. The temporary regulations provide guidance on the annual fee imposed on covered entities engaged in the business of manufacturing or importing branded prescription drugs. This fee was enacted by section 9008 of the Patient Protection and Affordable Care Act, as amended by section 1404 of the Health Care and Education Reconciliation Act of 2010.

    DATES:

    This correction is effective on September 28, 2011 and applies to any fee on branded prescription drug sales that is due on or after September 30, 2011.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Celia Gabrysh, (202) 622-3130 (not a toll-free number).

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Background

    Need for Correction

    As published August 18, 2001 (76 FR 51245), the tempoary regulations (TD 9544) contains errors that may prove to be misleading and are in need of clarification.

    Start List of Subjects

    List of Subjects in 26 CFR Part 51

    • Drugs
    • Reporting and recordkeeping requirements
    End List of Subjects

    Correction of Publication

    Accordingly, 26 CFR part 51 is corrected by making the following correcting amendments:

    Start Part

    PART 51—BRANDED PRESCRIPTION DRUG FEE

    End Part Start Amendment Part

    Paragraph 1. The authority citation for part 51 continues to read in part as follows:

    End Amendment Part Start Authority

    Authority: 26 U.S.C. 7805 * * *

    End Authority Start Amendment Part

    Par. 2. Section 51.2T is amended by revising paragraph (k)(1) to read as follows:

    End Amendment Part
    Explanation of terms (temporary).
    * * * * *

    (k) Orphan drugs—(1) In general. Except as provided in paragraph (k)(2) of this section, the term orphan drug means any branded prescription drug for which any person claimed a section 45C credit and that credit was allowed for any taxable year.

    * * * * *
    Start Amendment Part

    Par. 3. Section 51.7T is amended by revising the last sentence of paragraph (c)(2) to read as follows.

    End Amendment Part
    Dispute resolution process (temporary).
    * * * * *

    (c) * * *

    (2) * * * A form 2848 must be filed with the error report;

    * * * * *
    Start Amendment Part

    Par. 4. Section 51.8T is amended by revising paragraph (a)(2) to read as follows.

    End Amendment Part
    Notification and payment of fee (temporary).

    (a) * * *

    (2) After the 2011 fee year, the covered entity's adjustment amount

    calculated as described in § 51.5T(e);

    * * * * *
    Start Signature

    LaNita VanDyke,

    Chief, Publications and Regulations Branch, Legal Processing Division, Associate Chief Counsel (Procedure and Administration).

    End Signature End Supplemental Information

    [FR Doc. 2011-24903 Filed 9-27-11; 8:45 am]

    BILLING CODE 4830-01-P

Document Information

Comments Received:
0 Comments
Effective Date:
9/28/2011
Published:
09/28/2011
Department:
Internal Revenue Service
Entry Type:
Rule
Action:
Correcting amendment.
Document Number:
2011-24903
Dates:
This correction is effective on September 28, 2011 and applies to any fee on branded prescription drug sales that is due on or after September 30, 2011.
Pages:
59897-59897 (1 pages)
Docket Numbers:
TD 9544
RINs:
1545-BK34
Topics:
Drugs, Reporting and recordkeeping requirements
PDF File:
2011-24903.pdf
CFR: (3)
26 CFR 51.2T
26 CFR 51.7T
26 CFR 51.8T